Keyword Connections

Trastuzumab

Journals

7

1 erzincan Üniversitesi fen bilimleri enstitüsü dergisi

2 BMC cancer

3 chinese medical journal

4 Nature Cell Biology

5 The ISME journal

6 cancer chemotherapy and pharmacology

7 applied immunohistochemistry & molecular morphology : aimm

Research Groups

0

No Research Group Connected

Bibliographies

32

1 Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.

2 Differentially Expressed Genes in Matched Normal, Cancer, and Lymph Node Metastases Predict Clinical Outcomes in Patients With Breast Cancer.

3 Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.

4 radiolabeled antibody fragment for preparation of (<sub>177</sub>lu-dota)<sub>m</sub>-pamam g3.0-f(ab’)<sub>2</sub> trastuzumab as a radiopharmaceutical for cancer therapy

5 fcγriia and iiia polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer

6 clinical application of trastuzumab plus chemotherapy in the treatment of her2-positive gastric or gastro-oesophageal junction adenocarcinoma: a retrospective analysis of 75 cases

7 breast cancer clinical trial of chemotherapy and trastuzumab: potential tool to identify cardiac modifying variants of dilated cardiomyopathy

8 estudo da cinÉtica de secagem, extraÇÃo, caracterizaÇÃo e estabilidade tÉrmica do Óleo das sementes de maracujÁ do mato (passiflora cincinnata mast.)

9 pre-clinical assessment of 177lu-labeled trastuzumab targeting her2 for treatment and management of cancer patients with disseminated intraperitoneal disease

10 Assessment of HPLC-FLD Method for Determination of Trastuzumab

11 Assessment of HPLC-FLD Method for Determination of Trastuzumab

12 Assessment of HPLC-FLD Method for Determination of Trastuzumab

13 Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.

14 Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.

15 Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.

16 Public engagement in health technology assessment in Brazil: the case of the Trastuzumab public consultation.

17 Initiation of adjuvant chemotherapy and trastuzumab for human epidermal growth receptor 2-positive early invasive breast cancer in a population-based cohort study of older women in England.

18 Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

19 Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab

20 Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.

21 the efficacy of the combination of eribulin and trastuzumab in advanced her2-positive breast cancer: the results of russian observational study

22 her2/neu and trastuzumab

23 loss of her2 positivity after trastuzumab in her2-positive gastric cancer: is change in her2 status significantly frequent?

24 efeito isolado do anticorpo monoclonal trastuzumab (herceptin®) em uma paciente com recidiva local de um carcinoma mamário com hiper-expressão de cerb-2

25 is the improved efficacy of trastuzumab and lapatinib combination worth the added toxicity? a discussion of current evidence, recommendations, and ethical issues regarding dual her2-targeted therapy

26 effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer

27 dramatic clinical response of relapsed metastatic extramammary paget’s disease to trastuzumab monotherapy

28 effect of vh–vl families in pertuzumab and trastuzumab recombinant production, her2 and fcγiia binding

29 medical resource utilization for administration of trastuzumab in a new zealand oncology outpatient setting: a time and motion study

30 Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer.

31 Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience.

32 Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.